Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study

OBJECTIVES: To demonstrate the equivalent efficacy and compare the safety and immunogenicity of an etanercept biosimilar, GP2015, with reference etanercept (ETN) in patients with moderate-to-severe, active rheumatoid arthritis (RA), characterised by an inadequate response to synthetic or biologic di...

Descripción completa

Detalles Bibliográficos
Autores principales: Matucci-Cerinic, Marco, Allanore, Yannick, Kavanaugh, Arthur, Buch, Maya H, Schulze-Koops, Hendrik, Kucharz, Eugeniusz J, Woehling, Heike, Babic, Goran, Poetzl, Johann, Davis, Adanna, Schwebig, Arnd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242015/
https://www.ncbi.nlm.nih.gov/pubmed/30487998
http://dx.doi.org/10.1136/rmdopen-2018-000757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6242015/
https://www.ncbi.nlm.nih.gov/pubmed/30487998
http://dx.doi.org/10.1136/rmdopen-2018-000757

Ejemplares similares